Possible Interaction: Dexmedetomidine and Yohimbine

“Dexmedetomidine significantly inhibited the expression of TLR4 and NF-κB and activation of NF-κB. Yohimbine partly alleviated the effects of dexmedetomidine.”

“The α2-adrenergic receptor antagonist yohimbine (5 μg/kg) reduced the MPE of dexmedetomidine (30 μg/kg) both in wild type and knockout mice.”

“There were significant decreases in the contraction responses of cumulative dexmedetomidine with yohimbine (Emax: 12.1 ± 11.9 %), prazosin (Emax: 28.8 ± 4.6 %) and verapamil (Emax: 11.2 ± 13.6 %) (p < 0.05).”

“ Yohimbine , an α(2)-adrenergic receptor antagonist, completely neutralized the protective effect of Dexmedetomidine hydrochloride on Kupffer cells.”

“But in the presence of yohimbine , an α2-antagonist, dexmedetomidine suppressed platelet aggregation.”

“ Dexmedetomidine increased cGMP formation in platelets in the presence of yohimbine , and this increase was suppressed by efaroxan.”

“ Dexmedetomidine suppressed cAMP formation and enhanced P-selectin expression in platelets, and these effects were inhibited by yohimbine.”

“The effects of dexmedetomidine on 5-HT-induced vasoconstriction was suppressed by L-NAME and yohimbine , but not by indomethacin.”

“The suppressing effects of DEX on proinflammatory mediator production were reversed by yohimbine.”

“The contraction at lower concentrations of DEX (10(-9) mol/L-3 x 10(-7) mol/L) was attenuated by yohimbine (10(-7) mol/L), whereas prazosin (10(-8) mol/L) attenuated the contractions at higher concentrations of DEX (10(-6) mol/L-3 x 10(-5) mol/L).”

“ DEX markedly enhanced the high K+ (40 mmol/L)-induced contraction, and this effect was reversed by the &agr;2-adrenergic antagonists yohimbine and rauwolscine but unaffected by prazosin.”

“Intracerebroventricular application of atipamezole, yohimbine or BRL-44408 blocked the protection of dexmedetomidine on the brain but not on the systemic inflammation.”